Post by ashiwi on Mar 21, 2014 16:31:40 GMT -5
AF had a blog regarding Endocyte (ECTY)on Feb 25 with his reasons why it is a short.
www.thestreet.com/story/12441443/1/the-endocyte-bear-thesis-why-march-will-be-a-bad-month.html?puc=yahoo&cm_ven=YAHOO
NEW YORK (TheStreet) -- I believe Endocyte (ECYT_) is a short for two primary reasons. 1) European regulators are unlikely to grant conditional marketing approval to the company's experimental cancer drug vintafolide for the treatment of ovarian cancer; and 2) an ongoing phase II study of vintafolide in non-small cell lung cancer is likely to fail.
Well guess what happened today?
ECYT UP 13.53 92%
finance.yahoo.com/q?s=ecyt&ql=1
Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival
Expect the same reaction when Afrezza gets FDA approval next month.
www.thestreet.com/story/12441443/1/the-endocyte-bear-thesis-why-march-will-be-a-bad-month.html?puc=yahoo&cm_ven=YAHOO
NEW YORK (TheStreet) -- I believe Endocyte (ECYT_) is a short for two primary reasons. 1) European regulators are unlikely to grant conditional marketing approval to the company's experimental cancer drug vintafolide for the treatment of ovarian cancer; and 2) an ongoing phase II study of vintafolide in non-small cell lung cancer is likely to fail.
Well guess what happened today?
ECYT UP 13.53 92%
finance.yahoo.com/q?s=ecyt&ql=1
Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival
Expect the same reaction when Afrezza gets FDA approval next month.
